Insmed (NASDAQ:INSM) Earns “Buy” Rating from HC Wainwright

Insmed (NASDAQ:INSM)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $90.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 11.03% from the company’s previous close. HC Wainwright also issued estimates for Insmed’s Q1 2025 earnings at ($1.47) EPS, Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.41) EPS and Q4 2025 earnings at ($1.22) EPS.

INSM has been the subject of a number of other reports. Wells Fargo & Company raised their price target on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday. Truist Financial reissued a “buy” rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Guggenheim increased their price objective on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday, February 7th. Morgan Stanley increased their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Finally, JPMorgan Chase & Co. increased their price objective on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $91.00.

Insmed Stock Down 3.0 %

INSM opened at $81.06 on Friday. Insmed has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The business has a 50-day moving average of $74.29 and a 200-day moving average of $73.59. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company has a market capitalization of $14.50 billion, a PE ratio of -14.50 and a beta of 1.11.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Equities research analysts forecast that Insmed will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, CFO Sara Bonstein sold 18,322 shares of Insmed stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the sale, the chief financial officer now owns 118,863 shares of the company’s stock, valued at approximately $9,545,887.53. This trade represents a 13.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at $27,079,091.58. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 532,207 shares of company stock valued at $41,400,465 in the last 90 days. 4.60% of the stock is currently owned by insiders.

Institutional Trading of Insmed

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Insmed by 6.3% during the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock worth $1,257,838,000 after purchasing an additional 1,075,796 shares in the last quarter. Darwin Global Management Ltd. lifted its position in shares of Insmed by 23.5% during the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock worth $894,796,000 after buying an additional 2,463,261 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Insmed by 1.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company’s stock worth $877,113,000 after buying an additional 123,429 shares during the period. Capital International Investors lifted its position in shares of Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock worth $491,357,000 after buying an additional 593,206 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock worth $282,243,000 after buying an additional 273,759 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.